The prognosis of lipid reprogramming with the HMG-CoA reductase inhibitor, rosuvastatin, in castrated Egyptian prostate cancer patients: Randomized trial

• DOI: 10.1371/journal.pone.0278282
• Publication Date: 2022-12-08T18:32:35Z
• Authors: Riham M. Karkeet; Abdelrahman N. Zekri; Mohamed M. Sayed-...; Ghada M. Sherif; Salem E. Salem; Ahmed Abdelbary; Mariam A. Fouad; Sherif Y. Saad
• Keywords: Male; Pulmonary and Respiratory Medicine; Cancer Research; Science; Urology; Lipid Metabolism in Cancer Pathogenesis; Biochemistry; Rosuvastatin; 03 medical and health sciences; Advancements in Prostate Cancer Research; Endocrinology; 0302 clinical medicine; HMG-CoA reductase; Biochemistry, Genetics and Molecular Biology; Health Sciences; Humans; Metastatic Prostate Cancer; Castration; Rosuvastatin Calcium; Internal medicine; Biology; Pravastatin; Cancer; Reductase; Prostate cancer; Metabolic Reprogramming; Prostate Cancer; Q; R; Prostatic Neoplasms; Life Sciences; Statin; Lipids; 3. Good health; Cholesterol-lowering Treatment; Cholesterol; Enzyme; Medicine; Egypt; Surgery; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Oxidoreductases; Research Article

Aim The role of surgical castration and rosuvastatin treatment on lipid profile metabolism related markers was evaluated for their prognostic significance in metastatic prostate cancer (mPC) patients. Methods A total 84 newly diagnosed castrated mPC patients treated with were recruited divided into two groups: Group I served as control (statin non-users) while group II Rosuvastatin (20 mg/day) 6 months statin users. Prostate specific antigen (PSA), epidermal growth factor receptor (EGFR), Caveolin-1 (CAV1), (LDL, HDL, triglycerides (TG) cholesterol (TC)) (aldoketoreductase (AKR1C4), HMG-CoA reductase (HMGCR), ATP-binding cassette transporter A1 (ABCA1), soluble low density lipoprotein protein 1 (SLDLRP1)) measured at baseline, after 3 months. Overall survival (OS) analyzed by Kaplan-Meier COX regression significance. Results Before castration, elevated <65 years (P = 0.009). Bone metastasis associated high PSA level 0.013), but HMGCR 0.004). Patients positive family history showed levels EGFR, TG, TC, LDL, alkaline phosphatase (ALP), AKR1C4, SLDLRP1, CAV1 ABCA-1 levels. Smokers had 0.017). After administration, PSA, LDL TC significantly reduced, HMGCR, increased. reduced baseline SLDLRP1 (>3385 pg/ml, P 0.001), (>40 ng/ml, 0.003) (>4955 0.021). Conclusion the current study suggest that peripheral lipidogenic effects may have an impact outcome Trail registration This trial registered Pan African Clinical Trial Registry identification number PACTR202102664354163 ClinicalTrials.gov NCT04776889 .